Moxie was built to launch practices. The problem is it's priced and designed for that phase — and the established practice needs something different.
Moxie's value proposition — accelerator community, operational support, supply-chain relationships — is strongest in the first 12–24 months. For a practice that's still finding its footing, that scaffolding is genuinely valuable.
Once a practice is established — stable patient base, defined service menu, experienced injectors — the math shifts. The 9% gross override starts to cost $60K–100K+ per year. The supply relationships you leaned on early are now just a line item you could negotiate yourself. And the clinical tools that matter most — injection mapping, structured charting, consent automation, AI scribe integrated into the chart — become the bottleneck, not the partnerships.
That's the inflection. The same product that accelerated your launch starts working against your margin.
Based on what practices tell us when they reach out after outgrowing the accelerator model.
At $700K revenue, you're paying roughly $63K/yr in gross override alone — enough to fund a full-time clinical coordinator. That 9% fee made sense when Moxie was accelerating your launch. Once you have a stable patient base and a defined service menu, it's just overhead.
Moxie is not a clinical-first EMR. Structured treatment notes, consumable and lot tracking, device/energy settings, injection plotting, and consent gates are what working clinicians need every day — across every modality, not just injectables. Boulevard and Mangomint share the same gap: built for booking, not bedside.
Lock-in is the highest-confirmed churn driver across the medspa software market. Zenoti charges migration fees on top of multi-year terms. Boulevard runs 12-month minimums. Practices that have already given up one kind of lock-in (Moxie's 9%) aren't eager to trade it for another.
Most scribes produce a flat transcript and call it done. Established practices need the AI to fill the injection map, link the lot number, flag missing consent, and surface the prior visit — not just dictate a note that someone still has to manually transfer.
We designed Aesthetic EMR for the established practice that has outgrown the accelerator. Flat pricing at $399 per location per month, or $3,999 a year, the full platform included. Structured charting for every modality in the base tier — not a paid add-on. Usage-based costs (telephony, e-Rx) pass through at cost. AI scribe that writes into the chart: fills the injection map, links the lot number, flags consent gaps. Free self-serve data export in JSON, PDF, and CSV anytime you want it. Month-to-month. No surprise fees. No rev-share.
If you're still in the launch phase — under $300K revenue — and you're actively using Moxie's accelerator community, mentorship network, and supply partnerships, Moxie may genuinely be the right choice for where you are right now. We're not the right fit for practices that are still in the build phase and getting real value from that ecosystem. We're built for what comes next.
If you're past the launch phase and the 9% is starting to feel like dead weight, let's talk. No sales calls — just a look at whether the numbers make sense for your practice.
Request Early Access